Study analysis · Journal of Pain Research · 2025
Forget pain pills? A turmeric supplement eased knee pain in just 7 days—here's what a new study found.
A daily low-dose turmeric extract significantly reduced knee pain and improved daily function in people with mild-to-moderate knee arthritis, with benefits appearing within a week.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This is a well-run experiment where people with knee pain were randomly put into two groups: one got a turmeric pill, the other got a sugar pill, and nobody knew which one they had. This kind of test can show if the pill actually helps, because it's fair and unbiased. We can say the pill helped reduce knee pain, but we can't say it cures knee osteoarthritis or that it works for everyone or for a long time.
What’s the bottom line?
Turmeric is a spice that has a natural chemical called curcumin which might reduce pain and swelling. This study tested a special turmeric extract (WDTE60N) that your body can absorb easily. People with mild knee pain took one capsule (250 mg) every day for 3 months, while others got a fake pill (placebo). The study checked if their knee pain and daily activities got better.
How strong is this study?
The study was done very carefully: the patients were randomly assigned, neither the patients nor the doctors knew who got the real pill, and almost everyone finished the study. That makes the results pretty trustworthy. However, the company that makes the supplement paid for the study, and it only lasted 3 months, so we should still be a little careful.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
88 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=139)+10.0/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 584 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. While this is a properly randomized, double-blind, placebo-controlled trial, it is a single study with a relatively short follow-up (3 months) and a specific population (mild-to-moderate knee OA in India). Therefore, causal conclusions should be limited to this context. The design minimizes bias, but uncertainty remains regarding long-term effects and generalizability to other populations or disease severities.
Major COI
Major conflicts that significantly reduce study credibility
The study evaluates a proprietary turmeric extract manufactured by Nutriventia Limited and Laila Nutraceuticals, with a sponsor referenced in the methods. No explicit conflict of interest or funding statement is provided in the text, and the industry connection suggests a major conflict of interest.
Funders
Conflict Details
Nutriventia Limited / Laila Nutraceuticals: Manufacturer of the investigational product WDTE60N and likely sponsor of the trial.
Independent Analysis Safeguards
- Independent statistician generated randomization codes
- Double-blind design
The provided text lacks explicit COI or funding disclosures. The study product is a proprietary turmeric extract (WDTE60N) manufactured by Nutriventia Limited and Laila Nutraceuticals, and a sponsor is referenced in the methods, implying industry funding. The absence of disclosure and direct involvement of the product manufacturer in the trial raises concerns about bias, though the level of funder control is unclear.
Key takeaways
- 01
People taking turmeric had bigger drops in pain scores (14.4 points) than those taking placebo (6.0 points).
- 02
They also reported better everyday function and lower levels of inflammation in their blood.
- 03
Improvements started within one week and continued for 3 months.
- 04
Yes, these improvements are big enough to be felt by patients (clinically meaningful).
- 05
For example, pain relief was above the minimum important difference of 8.4 points by day 45, and all quality-of-life scores improved beyond the 8-point threshold.
- 06
The treatment was also safe with no serious side effects.
Surprising findings
- Significant pain reduction started at day 7, just one week into supplementation.Most natural supplements for arthritis are considered slow-acting; many people expect it to take weeks or months. This shows a relatively rapid onset.
- The effect size for pain relief (Cohen's d = 1.07) is considered 'large' - this is comparable to some prescription medications.Skeptics often dismiss dietary supplements as having little or no effect. This large effect size, if real, challenges that assumption.
- Inflammation markers (IL-6) actually increased slightly in the placebo group while decreasing in the turmeric group.It shows that without intervention, OA-related inflammation can worsen over time, while turmeric actively fought it.
Practical takeaways
If you have mild-to-moderate knee osteoarthritis, consider trying a high-bioavailability turmeric extract (look for water-dispersible or standardized curcuminoids) at around 250 mg per day, under a doctor's supervision.
This study only lasted 90 days and excluded severe OA; long-term safety is unknown. Also, not all supplements are created equal.
medium confidenceUse turmeric as a complementary approach, not a replacement for prescribed medication. It may help reduce pain and inflammation, but don't stop your current treatment without medical advice.
Potential interactions with blood thinners and other drugs; always consult a healthcare provider.
high confidenceTrack your symptoms for at least 45 days when trying turmeric for OA; the study suggests meaningful improvements may take 4-6 weeks.
Individual responses vary; some may see benefits earlier.
medium confidenceChoose supplements that specify the curcuminoid content (like this one with 60% curcuminoids) and are tested by third-party labs.
Regulation of supplements is lax; quality matters.
high confidenceWhy this study matters
Turmeric beats placebo for knee pain – fast
In a randomized double-blind trial, 70 patients took a novel water-dispersible turmeric extract (WDTE60N) 250 mg once daily for 90 days, while 69 took a placebo. The turmeric group's VAS pain score dropped by 14.41 points vs 6.02 for placebo (p<0.0001) — a large effect size of 1.07. Notably, significant pain relief appeared by day 7 and became clinically meaningful by day 45.
People with knee OA often struggle with chronic pain and want fast-acting, natural options. This study suggests a low-dose supplement can provide noticeable relief within a week.
Better than pain relief: improved function and quality of life
All five KOOS subscales (pain, symptoms, ADL, sport/recreation, QoL) improved significantly in the turmeric group by day 90, with effect sizes up to 1.53. Clinically important improvements (>8 points) were achieved in every domain.
Pain is subjective, but improvements in daily activities and quality of life mean patients can actually do things they couldn't before — like climbing stairs or walking longer distances.
Inflammation markers dropped significantly – this isn't just a placebo effect
After 90 days, inflammatory biomarkers hsCRP, TNF-alpha, IL-6, and IL-1beta were all significantly reduced compared to placebo. For example, hsCRP fell 21.11% in the turmeric group vs 4.95% placebo; IL-6 actually increased slightly in the placebo group.
Reduction in blood inflammatory markers suggests a genuine biological effect on the arthritis-related inflammatory pathway, not just masking of symptoms.
The 'low dose' breakthrough
The supplement provided 150 mg of curcuminoids in a single 250 mg capsule thanks to a water-dispersible technology that enhances absorption. Most turmeric extracts require 1000-2000 mg/day for similar effects.
This means you might get more benefit from a smaller pill, which could improve adherence and reduce stomach issues.
But don't throw away your meds yet – the caveats
The study was industry-funded (the product maker was involved), only lasted 90 days, and excluded severe OA. Long-term safety and effectiveness are unproven, and it wasn't compared head-to-head with NSAIDs.
It's crucial to interpret supplement claims skeptically. This study is promising but needs independent replication.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Turmeric is a spice that has a natural chemical called curcumin which might reduce pain and swelling. This study tested a special turmeric extract (WDTE60N) that your body can absorb easily. People with mild knee pain took one capsule (250 mg) every day for 3 months, while others got a fake pill (placebo). The study checked if their knee pain and daily activities got better.
Research results
People taking turmeric had bigger drops in pain scores (14.4 points) than those taking placebo (6.0 points). They also reported better everyday function and lower levels of inflammation in their blood. Improvements started within one week and continued for 3 months.
What this means - more context
Yes, these improvements are big enough to be felt by patients (clinically meaningful). For example, pain relief was above the minimum important difference of 8.4 points by day 45, and all quality-of-life scores improved beyond the 8-point threshold. The treatment was also safe with no serious side effects.
To evaluate the efficacy and safety of a novel low-dose water-dispersible turmeric extract (WDTE60N) at 250 mg once daily for 90 days in adults with mild-to-moderate knee osteoarthritis.
A double-blind, randomized, placebo-controlled trial in 139 adults with mild-to-moderate knee osteoarthritis found that WDTE60N significantly reduced knee pain, improved functional outcomes and quality of life, and reduced inflammatory markers compared to placebo. Benefits were observed as early as day 7, with clinically meaningful improvements by day 45, and the supplement was well tolerated.
Methods Used
Prospective, double-blind, randomized, parallel-group, placebo-controlled trial conducted at two orthopedic centers in India. Participants aged 45–75 with mild-to-moderate knee OA were randomized 1:1 to receive WDTE60N 250 mg or placebo once daily for 90 days. Outcomes included VAS pain, KOOS subscales, inflammatory biomarkers (hsCRP, TNF-α, IL-6, IL-1β), safety, and global assessments. Intention-to-treat and per-protocol analyses were performed.
Main Finding
WDTE60N produced significantly greater reductions in VAS pain score from baseline to day 90 (14.41 vs 6.02, p < 0.0001, Cohen's d = 1.07), with significant improvements starting at day 7. All five KOOS subscales improved significantly (p < 0.05), and inflammatory markers (hsCRP, TNF-α, IL-6, IL-1β) were reduced significantly (p < 0.0001, except IL-1β at day 45 p = 0.0128). Only one mild adverse event occurred in the turmeric group compared to three in placebo.
Confidence Level
High for a randomized controlled trial with double-blinding, adequate sample size, and effect sizes reported. However, the study is industry-funded (authors are employees of the supplement manufacturers) and short-term (90 days), so independent replication and longer-term data would increase confidence.
Study Flags
Red Flags
- •Industry-funded trial with authors employed by the supplement manufacturer
- •Short-term (90 days) follow-up; long-term efficacy and safety not assessed
- •Only mild-to-moderate knee OA patients included; results may not generalize to severe OA
Surprising Findings
Significant pain reduction started at day 7, just one week into supplementation.
Most natural supplements for arthritis are considered slow-acting; many people expect it to take weeks or months. This shows a relatively rapid onset.
Practical Takeaways
If you have mild-to-moderate knee osteoarthritis, consider trying a high-bioavailability turmeric extract (look for water-dispersible or standardized curcuminoids) at around 250 mg per day, under a doctor's supervision.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 584 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This is a well-run experiment where people with knee pain were randomly put into two groups: one got a turmeric pill, the other got a sugar pill, and nobody knew which one they had. This kind of test can show if the pill actually helps, because it's fair and unbiased. We can say the pill helped reduce knee pain, but we can't say it cures knee osteoarthritis or that it works for everyone or for a long time.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Low dropout rate (0.71%) and high adherence
- Adequate sample size with prospective power calculation
Weaknesses
- Short follow-up (3 months)
- Only two centers in a single country, limiting generalizability
- Conflicts of interest (authors employed by the product manufacturer)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Turmeric is a spice that has a natural chemical called curcumin which might reduce pain and swelling. This study tested a special turmeric extract (WDTE60N) that your body can absorb easily. People with mild knee pain took one capsule (250 mg) every day for 3 months, while others got a fake pill (placebo). The study checked if their knee pain and daily activities got better.
Research results
People taking turmeric had bigger drops in pain scores (14.4 points) than those taking placebo (6.0 points). They also reported better everyday function and lower levels of inflammation in their blood. Improvements started within one week and continued for 3 months.
What this means - more context
Yes, these improvements are big enough to be felt by patients (clinically meaningful). For example, pain relief was above the minimum important difference of 8.4 points by day 45, and all quality-of-life scores improved beyond the 8-point threshold. The treatment was also safe with no serious side effects.
To evaluate the efficacy and safety of a novel low-dose water-dispersible turmeric extract (WDTE60N) at 250 mg once daily for 90 days in adults with mild-to-moderate knee osteoarthritis.
A double-blind, randomized, placebo-controlled trial in 139 adults with mild-to-moderate knee osteoarthritis found that WDTE60N significantly reduced knee pain, improved functional outcomes and quality of life, and reduced inflammatory markers compared to placebo. Benefits were observed as early as day 7, with clinically meaningful improvements by day 45, and the supplement was well tolerated.
Methods Used
Prospective, double-blind, randomized, parallel-group, placebo-controlled trial conducted at two orthopedic centers in India. Participants aged 45–75 with mild-to-moderate knee OA were randomized 1:1 to receive WDTE60N 250 mg or placebo once daily for 90 days. Outcomes included VAS pain, KOOS subscales, inflammatory biomarkers (hsCRP, TNF-α, IL-6, IL-1β), safety, and global assessments. Intention-to-treat and per-protocol analyses were performed.
Main Finding
WDTE60N produced significantly greater reductions in VAS pain score from baseline to day 90 (14.41 vs 6.02, p < 0.0001, Cohen's d = 1.07), with significant improvements starting at day 7. All five KOOS subscales improved significantly (p < 0.05), and inflammatory markers (hsCRP, TNF-α, IL-6, IL-1β) were reduced significantly (p < 0.0001, except IL-1β at day 45 p = 0.0128). Only one mild adverse event occurred in the turmeric group compared to three in placebo.
Confidence Level
High for a randomized controlled trial with double-blinding, adequate sample size, and effect sizes reported. However, the study is industry-funded (authors are employees of the supplement manufacturers) and short-term (90 days), so independent replication and longer-term data would increase confidence.
Study Flags
Red Flags
- •Industry-funded trial with authors employed by the supplement manufacturer
- •Short-term (90 days) follow-up; long-term efficacy and safety not assessed
- •Only mild-to-moderate knee OA patients included; results may not generalize to severe OA
Surprising Findings
Significant pain reduction started at day 7, just one week into supplementation.
Most natural supplements for arthritis are considered slow-acting; many people expect it to take weeks or months. This shows a relatively rapid onset.
Practical Takeaways
If you have mild-to-moderate knee osteoarthritis, consider trying a high-bioavailability turmeric extract (look for water-dispersible or standardized curcuminoids) at around 250 mg per day, under a doctor's supervision.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 584 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This is a well-run experiment where people with knee pain were randomly put into two groups: one got a turmeric pill, the other got a sugar pill, and nobody knew which one they had. This kind of test can show if the pill actually helps, because it's fair and unbiased. We can say the pill helped reduce knee pain, but we can't say it cures knee osteoarthritis or that it works for everyone or for a long time.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Randomized, double-blind, placebo-controlled design
- Low dropout rate (0.71%) and high adherence
- Adequate sample size with prospective power calculation
Weaknesses
- Short follow-up (3 months)
- Only two centers in a single country, limiting generalizability
- Conflicts of interest (authors employed by the product manufacturer)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was done very carefully: the patients were randomly assigned, neither the patients nor the doctors knew who got the real pill, and almost everyone finished the study. That makes the results pretty trustworthy. However, the company that makes the supplement paid for the study, and it only lasted 3 months, so we should still be a little careful.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
88 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=139)+10.0/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 584 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. While this is a properly randomized, double-blind, placebo-controlled trial, it is a single study with a relatively short follow-up (3 months) and a specific population (mild-to-moderate knee OA in India). Therefore, causal conclusions should be limited to this context. The design minimizes bias, but uncertainty remains regarding long-term effects and generalizability to other populations or disease severities.
Major COI
Major conflicts that significantly reduce study credibility
The study evaluates a proprietary turmeric extract manufactured by Nutriventia Limited and Laila Nutraceuticals, with a sponsor referenced in the methods. No explicit conflict of interest or funding statement is provided in the text, and the industry connection suggests a major conflict of interest.
Funders
Conflict Details
Nutriventia Limited / Laila Nutraceuticals: Manufacturer of the investigational product WDTE60N and likely sponsor of the trial.
Independent Analysis Safeguards
- Independent statistician generated randomization codes
- Double-blind design
The provided text lacks explicit COI or funding disclosures. The study product is a proprietary turmeric extract (WDTE60N) manufactured by Nutriventia Limited and Laila Nutraceuticals, and a sponsor is referenced in the methods, implying industry funding. The absence of disclosure and direct involvement of the product manufacturer in the trial raises concerns about bias, though the level of funder control is unclear.